Jaen Juan C. Form 4 November 08, 2012

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

if no longer subject to Section 16. Form 4 or

Check this box

**SECURITIES** 

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person \* Jaen Juan C.

(First)

C/O CHEMOCENTRYX, INC., 850

(Street)

(State)

2. Issuer Name and Ticker or Trading Symbol

Issuer

ChemoCentryx, Inc. [CCXI]

3. Date of Earliest Transaction

(Month/Day/Year) 11/06/2012

below)

Director

X\_ Officer (give title \_ Other (specify

10% Owner

SVP, Drug Discovery & CSO

(Check all applicable)

5. Relationship of Reporting Person(s) to

4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Applicable Line)

> \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

**MAUDE AVENUE** 

Filed(Month/Day/Year)

(Zip)

(Middle)

**MOUNTAIN VIEW, CA 94043** 

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1.Title of<br>Security | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if | 3. 4. Securities Acquired (A) Transactionor Disposed of (D) |        |     | 5. Amount of Securities | 6.<br>Ownership  | 7. Nature of Indirect |            |
|------------------------|--------------------------------------|-------------------------------|---|--------|-----|-------------------------|------------------|-----------------------|------------|
| (Instr. 3)             | , ,                                  | any                           | Code (Instr. 3, 4 and 5)                                    |        |     | Beneficially            | Form:            | Beneficial            |            |
|                        |                                      | (Month/Day/Year)              | (Instr. 8)  |        |     |                         | Owned            | Direct (D)            | Ownership  |
|                        |                                      |                               |   |        |     |                         | Following        | or Indirect           | (Instr. 4) |
|                        |                                      |                               |   |        | (4) |                         | Reported         | (I)                   |            |
|                        |                                      |                               |   |        | (A) |                         | Transaction(s)   | (Instr. 4)            |            |
|                        |                                      |                               | Code V  | Amount |     | Price                   | (Instr. 3 and 4) |                       |            |
| C                      |                                      |                               |   |        |     | \$                      |                  |                       |            |
| Common<br>Stock        | 11/06/2012                           |                               | S(1)  | 5,833  | D   | 12.0059<br>(2)          | 55,000           | D                     |            |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: Jaen Juan C. - Form 4

| 1. Title of | 2.          | 3. Transaction Date | 3A. Deemed         | 4.         | 5.              | 6. Date Exerc | cisable and | 7. Titl | e and    | 8. Price of | 9. Nu  |
|-------------|-------------|---------------------|--------------------|------------|-----------------|---------------|-------------|---------|----------|-------------|--------|
| Derivative  | Conversion  | (Month/Day/Year)    | Execution Date, if | Transacti  | onNumber        | Expiration D  | ate         | Amou    | nt of    | Derivative  | Deriv  |
| Security    | or Exercise |                     | any                | Code       | of              | (Month/Day/   | Year)       | Under   | lying    | Security    | Secui  |
| (Instr. 3)  | Price of    |                     | (Month/Day/Year)   | (Instr. 8) | Derivative      | e             |             | Securi  | ties     | (Instr. 5)  | Bene   |
|             | Derivative  |                     |                    |            | Securities      |               |             | (Instr. | 3 and 4) |             | Owne   |
|             | Security    |                     |                    |            | Acquired        |               |             |         |          |             | Follo  |
|             | •           |                     |                    |            | (A) or          |               |             |         |          |             | Repo   |
|             |             |                     |                    |            | Disposed        |               |             |         |          |             | Trans  |
|             |             |                     |                    |            | of (D)          |               |             |         |          |             | (Instr |
|             |             |                     |                    |            | (Instr. 3,      |               |             |         |          |             | ·      |
|             |             |                     |                    |            | 4, and 5)       |               |             |         |          |             |        |
|             |             |                     |                    |            |                 |               |             |         |          |             |        |
|             |             |                     |                    |            |                 |               |             |         | Amount   |             |        |
|             |             |                     |                    |            |                 | Date          | Expiration  |         | or       |             |        |
|             |             |                     |                    |            |                 | Exercisable   | Date        | Title N | Number   |             |        |
|             |             |                     |                    | ~          | <i>(</i> 1) (5) |               |             |         | of       |             |        |
|             |             |                     |                    | Code V     | (A) (D)         |               |             |         | Shares   |             |        |

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Jaen Juan C.
C/O CHEMOCE

C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW, CA 94043

SVP, Drug Discovery & CSO

# **Signatures**

/s/ Susan M. Kanaya, as Attorney-in-Fact

11/08/2012

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from (2) \$11.95 to \$12.18 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2